Over the years, research has taken a disease that once was almost always fatal, to something that can be treated with a variety of therapies. Today, CML research continues and is accelerating rapidly. Hopefully, we will all one day witness a cure.
Until then, this page will serve to highlight research projects going on around the world. Projects will be broken out according to type, for example Curative vs. Quality of Life/Living with CML.
CML Biology for the Clinician in 2011 - The introduction of tyrosine kinase inhibitors into clinical practice has far exceeded expectations and resurrected hope that the fundamental insights from the "war on cancer" can lead to significant therapeutic advances. Nevertheless, the current perception among clinicians is that imatinib and its newer more potent cousins offer superb long-term disease control for most patients, but that cure without transplantation has remained elusive.
ASCO's new CancerProgress.net provides an interactive history of cancer research advancement. Users can select a particular type of cancer and see a timeline of discoveries/advances that have been made in treatment and care.
Catriona Jamieson, MD - CML Researcher UCSD named a Geoffrey Beene 2010 Rockstar of Science
Dr. Jamieson's team at UC San Diego discovered the in vivo identity of candidate leukemic stem cells (LSC) involved in the progression of a well-known myeloproliferative neoplasm, chronic myeloid leukemia (CML) to blast crisis, and a mechanism that promotes activation of LSC self-renewal.
Shaoguang Li, MD, PhD. - University of Massachusetts
Dr. Li's research focuses on targeting the leukemic stem cell and gaining a deeper understanding of the molecular characteristics of CML.
Tessa Holyoake, MD - Professor of Experimental Hematology - University of Glasgow
Dr. Holyoake's research focuses on cellular and molecular characterization of cancer stem cells in myeloid leukemias, particularly CML.
Advances in CML Research - Dr. Ravi Bhatia, City of Hope, Duarte, California
In this interview from the 2008 American Society of Hematology meeting in San Francisco, the Society's strategic partner, Patient Power, interviewed Dr. Bhatia to discuss residual disease and how researchers are trying to target that illusive CML Stem Cell or Leukemic Stem Cell (LSC). These cells are not eradicated through Tyrosine Kinase Inhibitors and can resurface/reactivate even when the disease is undetectable through PCR testing. (Keep in mind that this interview was conducted prior to Sprycel and Tasigna became available for front line therapy. Much progress continues to be made but this interview does a great job of discussing residual disease which continues to be problematic.)
The End of Cancer is Within Reach - Dr. Brian Druker
In this hour long video lecture, Dr. Druker talks about his research and the research of others that have brought about the great therapies available to us today.